600645 Vcanbio Cell & Gene Engineering Corp.,Ltd.
- 17.02
- +0.03+0.18%
Vcanbio Cell & Gene Engineering Corp.,Ltd. News
The selection system for accounting firms of Vcanbio Cell & Gene Engineering Corp., Ltd.
Announcement of the resolution of the 11th extraordinary meeting of the 11th board of directors of Vcanbio Cell & Gene Engineering Corp., Ltd.
Announcement of the results of share repurchase and share changes by vcanbio cell & gene engineering corp.,ltd.
Announcement on the Progress of Share Repurchase by vcanbio cell & gene engineering corp.,ltd.
Announcement on the Progress of Share Repurchase by vcanbio cell & gene engineering corp.,ltd.
Announcement of vcanbio cell & gene engineering corp.,ltd. obtaining acceptance notice for pharmaceutical clinical trial application by its wholly-owned subsidiary.
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the progress of share repurchase
Announcement of Resolutions of the 2023 Annual General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Legal Opinion of Beijing Guofeng Law Firm on the 2023 Annual General Meeting of Shareholders of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
An indicative announcement of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. on holding the 2023 Annual General Meeting of Shareholders
Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. 2023 Annual General Meeting of Shareholders Meeting Data
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on holding the 2023 Annual Results Briefing
Announcement on abnormal stock trading fluctuations of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd.
Reply to the inquiry letter on abnormal stock trading fluctuations of Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd.
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the progress of share repurchase
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on accruing asset impairment losses
Special report on the storage and actual use of funds raised by Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. in 2023
Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. 2023 Annual Report
Dongxing Securities Co., Ltd.'s special inspection opinion on the storage and use of funds raised by Zhongyuan Xiehe Cytogenetic Engineering Co., Ltd. in 2023
Announcement of Zhongyuan Xiehe Cell Genetic Engineering Co., Ltd. on the extension of the fund-raising project
Analysis
Price Target
No Data
